Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Peri-lesional injection requires precise anatomical knowledge and a higher technical skill level, and the marginal benefit over subcutaneous delivery is not clearly established
Regional Segment Analysis of the Interstitial Cystitis & Bladder Pain Syndrome (IC/BPS) Treatment Market North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA) North America is anticipated to hold the largest share of the interstitial cystitis & bladder pain syndrome (IC/BPS) treatment market over the predicted timeframe
For Cagri:AMY 3 R:G s , histidine side chains were predicted in the tautomeric state except H223, H302 (CTR), H18 (Cagri), H97 (RAMP3), H142, and H183 (G), which were modelled as tautomer
Among currently available biological drugs for treating psoriasis, TAC or markers of peroxidation were measured after treatment with anti-TNF- biologics (infliximab via intravenous administration of 5 mg/kg every 8 weeks for 6 months [21] or etanercept subcutaneously at a dosage of 50 mg biweekly for 12 weeks, followed by 25 mg biweekly for a further 12 weeks [62]) and anti-CD11a (efalizumab, weekly 1 mg/kg of body weight subcutaneous injections for 12 weeks [44])
